JP2023511358A5 - - Google Patents
Info
- Publication number
- JP2023511358A5 JP2023511358A5 JP2022544144A JP2022544144A JP2023511358A5 JP 2023511358 A5 JP2023511358 A5 JP 2023511358A5 JP 2022544144 A JP2022544144 A JP 2022544144A JP 2022544144 A JP2022544144 A JP 2022544144A JP 2023511358 A5 JP2023511358 A5 JP 2023511358A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- mydgf
- heart failure
- prevention
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20153008 | 2020-01-21 | ||
| EP20153008.6 | 2020-01-21 | ||
| PCT/EP2021/051079 WO2021148411A1 (en) | 2020-01-21 | 2021-01-19 | Myeloid-derived growth factor for use in treating or preventing fibrosis, hypertrophy or heart failure |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023511358A JP2023511358A (ja) | 2023-03-17 |
| JP2023511358A5 true JP2023511358A5 (https=) | 2024-01-26 |
| JP7777532B2 JP7777532B2 (ja) | 2025-11-28 |
Family
ID=69187588
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022544144A Active JP7777532B2 (ja) | 2020-01-21 | 2021-01-19 | 線維化、肥大または心不全の処置または予防における使用のための骨髄由来増殖因子 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230059560A1 (https=) |
| EP (1) | EP4093750A1 (https=) |
| JP (1) | JP7777532B2 (https=) |
| KR (1) | KR20220131262A (https=) |
| CN (1) | CN115698048A (https=) |
| AU (1) | AU2021211874A1 (https=) |
| BR (1) | BR112022014272A2 (https=) |
| CA (2) | CA3164500A1 (https=) |
| MX (1) | MX2022008727A (https=) |
| PH (1) | PH12022551792A1 (https=) |
| TW (1) | TW202142254A (https=) |
| WO (1) | WO2021148411A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11980654B2 (en) | 2020-09-22 | 2024-05-14 | Wisconsin Alumni Research Foundation | Method to inhibit neutrophil recruitment to damaged tissue using myeloid-derived growth factor |
| JP2024501821A (ja) | 2020-12-23 | 2024-01-16 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 心臓組織細胞に対する特異性を有するウイルスカプシドタンパク質 |
| CN115820829B (zh) * | 2022-03-22 | 2026-04-17 | 中国人民解放军军事科学院军事医学研究院 | Mydgf在防治记忆损伤及其相关疾病中的应用 |
| CA3258215A1 (en) | 2022-06-03 | 2023-12-07 | Boehringer Ingelheim International Gmbh | RECOMBINANT EXPRESSION OF THE MYELOID-DERIVED GROWTH FACTOR |
| CN120112304A (zh) | 2022-09-08 | 2025-06-06 | 勃林格殷格翰国际有限公司 | 用于治疗心源性休克的髓源性生长因子 |
| EP4480490A1 (en) * | 2023-06-23 | 2024-12-25 | Medizinische Hochschule Hannover | Brick1 for use in treating myocardial diseases |
| WO2025073372A1 (en) | 2023-10-05 | 2025-04-10 | Boehringer Ingelheim International Gmbh | Recombinant expression of myeloid-derived growth factor |
| WO2025120204A1 (en) | 2023-12-06 | 2025-06-12 | Boehringer Ingelheim International Gmbh | Novel formulation comprising myeloid-derived growth factor |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0173552B1 (en) | 1984-08-24 | 1991-10-09 | The Upjohn Company | Recombinant dna compounds and the expression of polypeptides such as tpa |
| WO1997047358A1 (en) | 1996-06-11 | 1997-12-18 | Merck & Co., Inc. | Synthetic hepatitis c genes |
| JP2001506484A (ja) | 1996-09-13 | 2001-05-22 | 財団法人相模中央化学研究所 | 分泌シグナル配列を有するヒト蛋白質およびそれをコードするｄｎａ |
| AU4220797A (en) * | 1996-09-13 | 1998-04-02 | Protegene Inc. | Human proteins having secretory signal sequences and DNAs encoding these prot eins |
| EP1578367A4 (en) | 2002-11-01 | 2012-05-02 | Genentech Inc | COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE DISEASES |
| WO2004069173A2 (en) | 2003-01-31 | 2004-08-19 | The Trustees Of The University Of Pennsylvania | Methods for modulating an inflammatory response |
| US20080004232A1 (en) | 2006-05-09 | 2008-01-03 | John Wilkins | Characterization of c19orf10, a Novel Synovial Protein |
| EP2130547A1 (en) | 2008-06-06 | 2009-12-09 | Giuliani International Limited | IL-25 for use in the treatment of inflammatory diseases |
| EP3747457A3 (en) | 2013-01-17 | 2021-03-03 | Medizinische Hochschule Hannover | Factor 1 protein, factor 2 protein and inhibitors thereof for use in treating or preventing diseases |
| KR20250133994A (ko) * | 2018-05-09 | 2025-09-09 | 케로스 테라퓨틱스, 인크. | 액티빈 수용체 유형 iia 변이체 및 그의 사용 방법 |
| WO2020176732A1 (en) * | 2019-02-27 | 2020-09-03 | Icahn School Of Medicine At Mount Sinai | TREATMENT OF PULMONARY FIBROSIS WITH SERCA2a GENE THERAPY |
-
2021
- 2021-01-19 MX MX2022008727A patent/MX2022008727A/es unknown
- 2021-01-19 EP EP21701283.0A patent/EP4093750A1/en active Pending
- 2021-01-19 TW TW110102010A patent/TW202142254A/zh unknown
- 2021-01-19 CA CA3164500A patent/CA3164500A1/en active Pending
- 2021-01-19 BR BR112022014272A patent/BR112022014272A2/pt unknown
- 2021-01-19 CA CA3223879A patent/CA3223879A1/en active Pending
- 2021-01-19 CN CN202180022864.1A patent/CN115698048A/zh active Pending
- 2021-01-19 WO PCT/EP2021/051079 patent/WO2021148411A1/en not_active Ceased
- 2021-01-19 US US17/759,056 patent/US20230059560A1/en active Pending
- 2021-01-19 KR KR1020227027546A patent/KR20220131262A/ko active Pending
- 2021-01-19 AU AU2021211874A patent/AU2021211874A1/en active Pending
- 2021-01-19 PH PH1/2022/551792A patent/PH12022551792A1/en unknown
- 2021-01-19 JP JP2022544144A patent/JP7777532B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023511358A5 (https=) | ||
| ES2332057T3 (es) | Muteinas del factor de crecimiento de fibroblastos 21. | |
| AU729463B2 (en) | Treatment of cardiomyopathy | |
| US11993638B2 (en) | GM-CSF mimetics and methods of making and using same | |
| JP2010174017A (ja) | Ｆｇｆの脈管形成的に有効な単位用量および投与方法 | |
| CN1466463A (zh) | 缺血性疾病治疗剂 | |
| WO2007097251A1 (ja) | 抗アミロイドβペプチド抗体産生誘導用のペプチドワクチン | |
| JP2010512393A5 (https=) | ||
| JP2014506787A5 (https=) | ||
| Bourdillon et al. | Salbutamol in treatment of heart failure. | |
| JP2022500078A5 (https=) | ||
| JP2020040988A (ja) | 長時間作用型アドレノメデュリン誘導体 | |
| JP2019521976A5 (https=) | ||
| US9060977B2 (en) | Heparin binding epidermal growth factor (HB-EGF) for use in methods of treating and preventing intestinal injury related to hemorrhagic shock and resuscitation | |
| EP2413954B1 (en) | Composition comprising vip or its active fragments for use in treating aortic fibrosis | |
| US8404653B2 (en) | Membrane bound stem cell factor therapy for ischemic heart | |
| JP2005206544A (ja) | 筋肉再生剤 | |
| US8940697B2 (en) | Compositions and methods for the treatment of myocardial ischemia/reperfusion injury with Annexin A1 short peptide | |
| WO2020035012A1 (zh) | 神经调节蛋白多肽片段及其用途 | |
| IL318509A (en) | Myeloid-derived growth factor for use in the treatment of cardiogenic shock | |
| CN101890155A (zh) | 一种药物组合物及其应用 | |
| CN101356190B (zh) | 用于抑制pf4和rantes相互作用的拮抗剂 | |
| JP2023509067A (ja) | コドン最適化ＴＩＦ１γポリヌクレオチドを含む組換えベクターおよびその用途 | |
| WO2020123611A1 (en) | Choline acetyltransferase as a therapy for hypertension | |
| WO2012138043A2 (en) | Therapeutic composition containing endothelin as an active component |